Phase 3 SELVA trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for the treatment of microcystic lymphatic malformations (microcystic LMs) has exceeded enrollment target of 40 patients; enrollment expected to close in June 2025 Phase 3 SELVA trial top-line results anticipated in the first quarter of 2026 Phase 2 TOIVA trial evaluating QTORIN™ rapamycin for the treatment of cutaneous venous malformations top-line results on track for the fourth quarter of 2025 QTORIN™ rapamycin has th ...

Core Viewpoint - Palvella Therapeutics, Inc. is set to report its first quarter 2025 financial results on May 15, 2025, and will host a conference call to discuss these results and provide a corporate update [1][2]. Company Overview - Palvella Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for serious, rare genetic skin diseases that lack FDA-approved treatments [4]. - The company is developing a pipeline of product candidates utilizing its patented QTORIN™ platform, with a primary focus on lifelong serious genetic skin diseases [4]. - The lead product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently undergoing evaluation in the Phase 3 SELVA clinical trial for microcystic lymphatic malformations and the Phase 2 TOIVA clinical trial for cutaneous venous malformations [4]. Financial Communication - A conference call for investors will take place at 8:30 a.m. ET on May 15, 2025, to discuss the financial results and provide updates on corporate activities [2]. - The call will be accessible via a live webcast and by phone, with a replay available approximately two hours after the call [3].